News

WuXi MedImmune Biopharmaceutical is a joint venture (JV) formed in September 2012 by AstraZeneca’s global biologics research and development arm MedImmune, and WuXi AppTec. The JV was created

The validation of MAA confirms that the submission is complete and signifies the start of the review process by the EMA’s Committee for Medicinal Products for Human Use

In May last year, the company submitted a NDA to the FDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act, as amended, for approval of

The meningitis B vaccine will be introduced as part of the National Health Service’s (NHS) NHS immunization program, which is scheduled to be initiated in September. UK Health

Lenvima is an orally administered molecular targeted agent which inhibits the activities of several different molecules such as VEGFR, FGFR, RET, KIT and PDGFR. Mainly, the agent simultaneously

Gadovist is the first high concentration/high relaxivity gadolinium-based contrast agent to be approved in Japan. In Japan, there are more than 1.6 million MRI procedures conducted each year

The open label, multi-dose, safety and pharmacokinetic (PK) study is expected to enroll around 46 subjects with schizophrenia or schizoaffective disorder. Relday has been designed to offer potentially

Zafatek (trelagliptin succinate) controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones

Sovaldi, a once-daily nucleotide analog polymerase inhibitor, is indicated for use in combination with ribavirin (RBV) for 12 weeks and the combination is the first all-oral, interferon-free treatment